Eli Lilly and Co

Most Recent

  • Is Eli Lilly or LLY Stock a Buy or Sell?
    Healthcare

    Eli Lilly Stock Looks Like a Buy on Dips Amid Strong Growth Outlook

    By Ambrish Shah
  • Eli Lilly's Antibody Therapy is Promising, Lilly to Buy Prevail Therapeutics
    Healthcare

    Eli Lilly Will Buy Prevail Therapeutics, COVID-19 Antibody Therapy Is Promising

    By Ambrish Shah
  • uploads///Chart
    Company & Industry Overviews

    Merck & Co.’s Animal Health Segment

    The revenues of Merck & Co.’s Animal Health segment have improved due to increased sales in the Companion Animal Products segment.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Eli Lilly’s 1Q18 Earnings by Segment

    Eli Lilly’s (LLY) products are classified into two business segments: Human Pharmaceutical Products and Animal Health Products.

    By Mike Benson
  • uploads///Novo RV multiples
    Earnings Report

    Is Novo Nordisk Trading at a Discount or Premium?

    For the last five years, Novo Nordisk (NVO) has been trading at higher multiples when compared with peers.

    By Jillian Dabney
  • uploads///Chart
    Company & Industry Overviews

    A Look at Johnson & Johnson’s Post-2Q17 Valuation

    Headquartered in New Jersey, Johnson & Johnson (JNJ) is one of the largest pharmaceutical companies, with its products sold in over 200 countries worldwide. This series will look at how it has performed since its 2Q17 earnings announcement.

    By Mike Benson
  • uploads///Article
    Company & Industry Overviews

    Lilly’s Total Returns Are Lower than Some Pharma ETFs

    The total return for Lilly’s share price on the NYSE from July 2010 to June 2015 has been around 17.9%. This is lower than a few of the pharmaceutical ETFs.

    By Mike Benson
  • uploads///Taltz
    Company & Industry Overviews

    Eli Lilly’s Immunology Business Saw Solid Growth in 2017

    In 4Q17, Eli Lilly’s (LLY) Taltz generated revenues of $172.5 million compared to $61.3 million in 4Q16.

    By Daniel Collins
  • uploads///Graph
    Company & Industry Overviews

    What Are Analysts’ Recommendations for Merck in 2017?

    For 2016, Merck & Co. (MRK) reported revenue close to $39.8 billion, a year-over-year (or YoY) rise of ~1%. New product launches have played major roles in boosting Merck’s 2016 revenue.

    By Margaret Patrick
  • uploads///Chart
    Earnings Report

    Johnson & Johnson’s Valuation Cheat Sheet

    On January 26, 2017, the company was trading at a forward PE of ~15.8x. Based on the last five years’ multiple range, JNJ’s current valuation is neither high nor low.

    By Mike Benson
  • uploads///Graph
    Company & Industry Overviews

    What Analysts Think about Bristol-Myers Squibb

    Of 28 analysts covering BMY’s stock, 42.3% gave it a “buy” recommendation, while 50.0% gave it a “hold” recommendation. Only 7.7% rated it as a “sell.”

    By Margaret Patrick
  • uploads///ANR
    Company & Industry Overviews

    Analysts’ Expectations for Sanofi

    According to a March 3, 2016, Bloomberg consensus of five brokerage firms, 60% of brokerage firms rated Sanofi as a “buy,” while 40% of the broker firms rated the company as a “hold.”

    By Jillian Dabney
  • uploads///Chart
    Earnings Report

    What Analysts Project for Eli Lilly in 3Q17

    For 3Q17, analysts estimate that Eli Lilly will post EPS of $1.03 on revenues of $5.5 billion.

    By Mike Benson
  • uploads///Part  Graph
    Company & Industry Overviews

    Inside XLV’s Large Caps: Pfizer’s 1Q16 Earnings

    Pfizer recently rose by 2.7% on revenues of $13 billion for 1Q16, as compared to $10.9 billion in 1Q15, which represents a growth of 20% YoY.

    By Peter Neil
  • uploads///Graph
    Company & Industry Overviews

    Label Expansion Expected to Boost Keytruda’s 2017 Revenue

    On October 24, 2016, the FDA approved Merck & Co’s (MRK) Keytruda as a second-line therapy for patients suffering from non-small cell lung cancer (or NSCLC).

    By Margaret Patrick
  • uploads///close up _
    Earnings Report

    Pfizer Missed Analysts’ Third-Quarter Revenue Estimates

    Pfizer (PFE) released its third-quarter earnings on October 30.

    By Mike Benson
  • uploads///syringe _
    Company & Industry Overviews

    Assessing Novartis’s Performance in October So Far

    Novartis’s ADR (American depositary receipt) has fallen ~1.0% to date in October, while it’s risen nearly 3.3% in the last month.

    By Mike Benson
  • uploads///BRCM
    Earnings Report

    Highfields Capital exits its position in Broadcom

    Highfields Capital sold its position in BRCM in the third quarter. The position accounted for 1.66% of the fund’s 2Q14 portfolio. Broadcom makes semiconductors for wired and wireless communications.

    By Diana Key
  • uploads///Graph
    Company & Industry Overviews

    Valeant’s Dermatology Business Felt Pricing Pressure in 2016

    Dermatology pricing trends Valeant Pharmaceuticals’ (VRX) dermatology business witnessed intense pricing pressure in 2016, due to a change in the company’s distribution model in 4Q15. While Valeant previously marketed its dermatology drugs through specialty pharmacies, the company now distributes its products through Walgreens. To learn about the company’s current distribution model, please refer to How Valeant Plans […]

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Siliq May be a Strong Growth Driver for Valeant in 2017

    Siliq growth trends On February 15, 2017, the FDA approved injectable biologic therapy Siliq (brodalumab) as a treatment option for moderate-to-severe plaque psoriasis patients. Siliq is for psoriasis patients eligible for systemic therapy or phototherapy, and are not responding sufficiently or have stopped responding to these treatment options. To learn more about Siliq, please refer to What Are […]

    By Margaret Patrick
  • uploads///molecule _
    Company & Industry Overviews

    Wall Street Analysts: Mostly Positive on Opko Health in July

    On July 11, Opko Health (OPK) stock closed at $6.01, which represents 126% growth from its 52-week low of $2.66 in March.

    By Daniel Collins
  • uploads///pill _
    Company & Industry Overviews

    Why Incyte Stock Fell ~9% on April 24

    On April 24, Incyte (INCY) stock fell ~9% on news regarding its drug Baricitinib, which is under FDA review.

    By Sarah Collins
  • uploads///medicine _
    Company & Industry Overviews

    Mylan Launches First Adcirca Generic, Stock Moves Up

    Mylan Pharmaceuticals (MYL) announced the launch of tadalafil tablets USP (20 mg) in the United States.

    By Sarah Collins
  • uploads///Oncology
    Company & Industry Overviews

    A Post-2Q17 Update on Pfizer’s Oncology Drugs: Sutent, Xalkori, and Inlyta

    In 2Q17, Inlyta generated revenues of ~$88 million, which represents an ~19% decline on a YoY basis and ~4% growth on a quarter-over-quarter basis.

    By Daniel Collins
  • uploads///Graph
    Earnings Report

    Biogen Pursuing Investigational Candidates in Alzheimer’s Disease

    Biogen (BIIB) has entered into a licensing agreement with Bristol-Myers Squibb (BMY) for exclusive global rights for the development and commercialization of BMS-986168.

    By Margaret Patrick
  • uploads///Chart
    Earnings Report

    What to Expect from Pfizer’s 2Q16 Earnings

    In Pfizer’s 2Q16 results, analysts expect to see EPS (or earnings-per-share) of $0.62 and revenues of ~$13.0 billion for 2Q16. The company has surpassed Wall Street analysts’ estimates for EPS over the last few quarters.

    By Mike Benson
  • uploads///valuation
    Company & Industry Overviews

    Investor Insights: Teva Pharmaceutical’s Valuation Multiples

    On October 11, Teva Pharmaceutical Industries (TEVA) was trading at a forward PE (price-to-earnings) ratio of 7.5x compared to the industry average PE of 11.5x.

    By Sarah Collins
  • uploads///Graph
    Company & Industry Overviews

    Novo Nordisk Is Focusing on These Strategic Areas in 2016

    With 642 million people expected to suffer from diabetes globally by 2040, the disease is expected to offer multiple growth opportunities for Novo Nordisk.

    By Margaret Patrick
  • uploads///tablets _
    Earnings Report

    Teva Stock Rises on Strong 1Q18 Results, Outlook Up

    Today, Teva Pharmaceutical Industries (TEVA) released its 1Q18 earnings results for the quarter that ended on March 31.

    By Sarah Collins
  • uploads///Graph
    Company & Industry Overviews

    Amgen: Exploring Opportunities in the Bone Segment

    Amgen’s Prolia is the leading brand for treating postmenopausal osteoporosis, or PMO, in women with a high risk of bone fracture.

    By Margaret Patrick
  • uploads///ibrance
    Company & Industry Overviews

    Ibrance Is the Only Registered CDK 4/6 Inhibitor for Breast Cancer

    Since its launch in February 2015, Pfizer’s Ibrance has quickly captured the advanced breast cancer market and has reached more than 40,000 patients.

    By Jillian Dabney
  • uploads///drug _
    Earnings Report

    Analysts’ Recommendations for Sanofi Stock before Q2 Results

    Sanofi (SNY) is scheduled to announce its earnings results for the second quarter of fiscal 2018 on July 31.

    By Sarah Collins
  • uploads///Chart
    Earnings Report

    How Analysts Rate Bristol-Myers Squibb in 1Q18

    Wall Street analysts estimate Bristol-Myers Squibb’s top line to rise 6.5% to ~$5.2 billion in 1Q18.

    By Mike Benson
  • Healthcare

    Why AstraZeneca’s oncology pipeline is attractive to Pfizer

    Pfizer (PFE) is seeking to expand its oncology franchise and a combination with AstraZeneca (AZN) would be meaningful due to the latter’s pipeline of cancer drugs.

    By Samantha Nielson
  • uploads///pina messina  unsplash
    Company & Industry Overviews

    Eli Lilly’s Valuation on May 17

    On May 17, Eli Lilly was trading at a forward PE multiple of 15.2x, which compares to the industry average of 13.6x.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    GlaxoSmithKline Increases Top Line in 2Q16

    GlaxoSmithKline (GSK) reported a 10.9% increase in its top line in its 2Q16 earnings on July 27, 2016. It met Wall Street analysts’ estimates for revenues and EPS.

    By Mike Benson
  • uploads///Kisqali BTD
    Company & Industry Overviews

    Novartis Receives 2 Breakthrough Therapy Designations in January

    In January 2018, the FDA granted a BTD to Novartis’s (NVS) Promacta for use along with standard immunosuppressive therapy.

    By Daniel Collins
  • uploads///dna _
    Company & Industry Overviews

    European Medicines Agency Validates Merck’s Keytruda Combo

    Merck’s (MRK) Keytruda (pembrolizumab) is approved to treat various forms of cancer.

    By Mike Benson
  • uploads///DIABETES
    Company & Industry Overviews

    Johnson & Johnson Gets FDA Approval for Type 2 Diabetes Drug

    On September 21, 2016, the FDA approved Jannsen Pharmaceuticals’ Invokamet XR for the treatment of adults suffering from Type 2 diabetes.

    By Sarah Collins
  • uploads///sales estimates
    Company & Industry Overviews

    Competition Dynamics for Ajovy—Teva’s Migraine Drug

    Approved by the FDA on September 14, Teva’s Ajovy has multiple competitors set to enter the market.

    By Sarah Collins
  • uploads///featured image
    Company & Industry Overviews

    An Overview of Valeant Pharmaceuticals’ Performance in 1Q18

    Valeant Pharmaceuticals (VRX) announced that it would change its name to Bausch Health Companies, which is expected to be effective in July.

    By Daniel Collins
  • uploads///Chart
    Earnings Report

    Eli Lilly’s 1Q18 Earnings: Neuroscience Products Portfolio

    Cymbalta, an antidepressant drug, reported revenues of $169.6 million in 1Q18, a 3% growth compared to $174.6 million in 1Q17.

    By Mike Benson
  • uploads///specialty products pipeline
    Company & Industry Overviews

    Non-Opioid Pain Therapy Market Opportunity for Teva

    The Trump administration proposed production cuts in some of the most abused opioid compounds by 10% next year.

    By Sarah Collins
  • uploads///HBbuysell
    Consumer

    Overview: Highbridge Capital Management’s 2Q14 positions

    Highbridge Capital Management is an alternative investment management organization. It was founded in 1992. The company has developed a diversified investment platform.

    By Patricia Garner
  • uploads///Chart
    Company & Industry Overviews

    Pfizer’s Growth Rate and Estimates

    Pfizer (PFE) reported an EPS of $0.74 on revenues of ~$13.5 billion during the second quarter, which beat analysts’ estimate of ~$13.3 billion.

    By Mike Benson
  • uploads///Diabetes
    Company & Industry Overviews

    Januvia and Janument: An Update on Merck’s Diabetes Franchise after 2Q17

    In 2Q17, Merck’s (MRK) Januvia generated revenues of around $948 million, which reflected an ~11% decline on a year-over-year basis and 13% growth on a quarter-over-quarter basis.

    By Daniel Collins
  • uploads///Graph
    Company & Industry Overviews

    Novo Nordisk Continues to Be a Leader in the Global Insulin Market

    Accounting for a ~46% market share, Novo Nordisk (NVO) is expected to continue to benefit from the positive trends in the global insulin market

    By Margaret Patrick
  • uploads///thermometer _
    Earnings Report

    Eli Lilly and Co.’s Strong Q1 Results, Updated 2018 Guidance

    Eli Lilly and Co. reported revenues of ~$5.7 billion for 1Q18 today, reflecting 9% growth from 1Q17.

    By Mike Benson
  • uploads///Graph
    Company & Industry Overviews

    Opdivo Is a Key Growth Driver for Bristol-Myers Squibb in 2016

    On November 10, 2016, the FDA approved Opdivo as a treatment option for patients suffering with recurring or metastatic squamous cell carcinoma of the head and neck (or SCCHN).

    By Margaret Patrick
  • uploads///pill _
    Company & Industry Overviews

    Sanofi Stock: How Much Upside Potential Does Wall Street See?

    In the second quarter of fiscal 2018, Sanofi (SNY) reported sales of 8.2 billion euros, a YoY (year-over-year) decline in sales as well as profits.

    By Sarah Collins
  • uploads///Graph
    Company & Industry Overviews

    Entering Migraine Market Won’t Be Easy for Novartis, Amgen

    Novartis (NVS) and Amgen (AMGN) recently announced that the CGRP inhibitor therapy, AMG 334, reported positive results in a Phase 2 clinical trial as a therapy for preventing chronic migraine.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    What Will Be a Key Driver of Biogen’s Future Valuations?

    Biogen’s investigational Alzheimer’s disease drug, aducanumab, is one of the four therapies accepted in the EMA’s Priority Medicines program (or PRIME).

    By Margaret Patrick
  • uploads///Acq
    Company & Industry Overviews

    Mylan’s Recent Acquisitions Continue to Strengthen Its Position in International Markets

    Mylan takes an M&A strategy to save time related to compliance activities for obtaining regulatory approvals across various international markets.

    By Seth Richards
  • uploads///Chart
    Earnings Report

    Analyzing Johnson & Johnson’s Segment-Wise Performance in 1Q18

    Johnson & Johnson reported growth across all three of its segments: the pharmaceutical segment, the consumer health segment, and the medical devices segment.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    How Merial Contributes to Sanofi’s Growth

    Merial, Sanofi’s (SNY) Animal Health segment, reported total revenues of 725 million euros (about $818.6 million), which is a 9.1% increase over 2Q15.

    By Mike Benson
  • uploads///XOM
    Consumer

    Must-know: Highfields Capital exits a position in Exxon Mobil

    Highfields Capital exited a position in Exxon Mobil that accounted for 1.67% of the fund’s 1Q14 (or the first quarter of 2014) portfolio.

    By Samantha Nielson
  • uploads///dna _
    Company & Industry Overviews

    Merck’s Relebactam Met Primary Endpoints in Phase 3 Study

    Merck’s Relebactam is an investigational drug for the treatment of certain forms of imipenem-non-susceptible bacterial infections.

    By Mike Benson
  • uploads///virus _
    Earnings Report

    Bristol-Myers Squibb’s 1Q18 Earnings Beat Wall Street Estimates

    Bristol-Myers Squibb beat Wall Street analysts’ estimates for earnings per share and revenues in 1Q18.

    By Mike Benson
  • uploads///Recent wins
    Earnings Report

    Brodalumab, Oral Relistor among Valeant’s Recent Wins

    Valeant’s (VRX) recent wins include the FDA’s advisory committee vote in favor of approving brodalumab for the indication of mild to moderate psoriasis.

    By Jillian Dabney
  • uploads///Chart
    Earnings Report

    Eli Lilly’s 1Q18 Earnings: Cardiovascular Products Portfolio

    Eli Lilly’s (LLY) Human Pharmaceuticals business includes cardiovascular products Effient, Cialis, and Adcirca, which reported lower sales in 1Q18.

    By Mike Benson
  • uploads///SHighfields Q positions
    Financials

    Highfields Capital Management’s positions in 3Q14

    Highfields Capital Management LP is based in Boston. The fund was founded by Jonathon Jacobson in 1998. The fund’s US long portfolio declined slightly to $12.8 billion in the third quarter.

    By Diana Key
  • uploads///Graph
    Company & Industry Overviews

    The Latest on Fasinumab, a Teva-Regeneron Collaborative Drug

    On October 17, 2016, Teva and Regeneron announced that the FDA had placed the Phase 2 study for fasinumab on clinical hold.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Olumiant Could Boost Incyte’s Revenues

    In February 2017, Eli Lilly (LLY) secured approval for Olumiant (baricitinib) from the European Medicines Agency (or EMA) for patients suffering from moderate-to-severe rheumatoid arthritis.

    By Margaret Patrick
  • uploads///LLY
    Consumer

    Must-know: Highfields Capital starts a new position in Eli Lilly

    Highfields Capital initiated a new position in Eli Lilly and Company that accounts for 2.13% of the fund’s 2Q14 (or second quarter of 2014) portfolio.

    By Samantha Nielson
  • uploads///dna _
    Earnings Report

    Pfizer Reports 1Q18 Earnings and Revenue Growth

    Pfizer (PFE) released its 1Q18 earnings today, reporting another strong quarter for the Innovative health business.

    By Mike Benson
  • uploads///checklist _
    Healthcare

    Major M&A Deals in Pharmaceutical Sector in May and June

    On June 1, GlaxoSmithKline (GSK) completed the buyout of a 36.5% stake in Novartis (NVS) in a consumer healthcare joint venture.

    By Mike Benson
  • uploads///Animal Health Segment
    Earnings Report

    How Did Merial Contribute to Sanofi’s 2Q15 Growth?

    Merial reported total revenues of 691 million euros, a 14.2% increase at constant exchange rates over 2Q14.

    By Mike Benson
  • uploads///portfolio
    Company & Industry Overviews

    Ligand Pharmaceuticals’s Portfolio Pyramid as Its Valuation Catalyst

    Ligand Pharmaceuticals’s (LGND) product portfolio has expanded from nine programs in 2008 to 140+ programs in 2016.

    By Jillian Dabney
  • uploads///novartis
    Fund Managers

    Maverick Capital Increases Stake in Novartis

    Maverick Capital increased its position in Novartis (NVS) by more than $22 million in stock. It represented 0.75% of the fund’s total portfolio in 4Q14.

    By Patricia Garner
  • uploads///pills _
    Company & Industry Overviews

    Teva Announces First-to-File Launch of Generic Cialis

    Yesterday, Teva Pharmaceutical Industries (TEVA) announced the exclusive FTF (first-to-file) launch of the generic Cialis1 tablets in the US.

    By Sarah Collins
  • uploads///Abraxane
    Company & Industry Overviews

    How’s Celgene’s Abraxane Positioned after 4Q17?

    In 4Q17, Celgene’s (CELG) Abraxane generated revenues of $251 million, which reflected a decline of ~6% on a YoY (year-over-year) basis.

    By Daniel Collins
  • Why the US Moat Index Beat the S&P 500 Index in July
    Healthcare

    Why the US Moat Index Beat the S&P 500 Index in July

    Domestic moat companies, as represented by the Morningstar® Wide Moat Focus IndexSM (MWMFTR, or “U.S. Moat Index”), once again posted strong results in July.

    By VanEck
  • eli lilly stock down earnings
    Financials

    Should You Buy Eli Lilly Stock After Its Q3 Earnings?

    By Ruchi Gupta
  • Trump Pushes Regeneron and Eli Lilly Antibodies for COVID-19, Stocks Up
    Healthcare

    Trump Pushes Regeneron and Eli Lilly Antibodies for COVID-19, Stocks Up

    By Ambrish Shah
  • uploads///patent cliff top
    Company & Industry Overviews

    Why the Patent Cliff Is a Key Driver of Generic Drug Growth

    Over the last several years, patent cliffs have led to steep revenue losses for traditional pharmaceuticals as well as created a gateway for smaller companies to come to market with generics.

    By VanEck
  • uploads///Chart
    Earnings Report

    Why Eli Lilly Expects 2Q17 Revenue Growth

    As per analysts’ estimates, Eli Lilly’s (LLY) revenues could rise ~3.6% to $5.6 billion in 2Q17.

    By Mike Benson
  • uploads///Bausch
    Company & Industry Overviews

    A Financial Overview of Bausch Health in October

    Bausch Health’s (BHC) net revenues declined from $4.3 billion in H1 2017 to $4.1 billion in H1 2018, reflecting an ~5.0% year-over-year decline.

    By Daniel Collins
  • uploads///Chart
    Company & Industry Overviews

    How Eli Lilly’s Cardiovascular Products Have Been Faring

    Eli Lilly and Company’s (LLY) Human Pharmaceutical segment includes cardiovascular products such as Cialis, Effient, and other products.

    By Mike Benson
  • uploads///pill _
    Healthcare

    These Pharma Stocks Offer the Most Upside Potential

    In 2018, stock markets, especially in the pharmaceutical sector, have seen heightened volatility.

    By Kenneth Smith
  • uploads///microbiology Picture
    Company & Industry Overviews

    Wall Street Analysts Are Mostly Positive about Johnson & Johnson

    In June, Johnson & Johnson (JNJ) accepted a binding offer from Platinum Equity to acquire its LifeScan business for ~$2.1 billion.

    By Daniel Collins
  • uploads///three black crows
    Financials

    Three Black Crows And Three White Soldiers Candlestick Pattern

    The Three White Soldiers candlestick pattern is also a reversal pattern. It forms at the bottom of a downtrend. The pattern has three candles. All three of the candles are long and bullish.

    By Gordon Kristopher
  • uploads///Zoetis Business Model
    Financials

    Zoetis: An attractive business model

    Zoetis said in a recent statement that “its unique characteristics have established the company as the world leader in animal health, growing revenue faster than the market for the last three years.”

    By Samantha Nielson
  • uploads///ZTS industry stats
    Consumer

    Must-know trends that drive Zoetis’ growth

    Demand for Zoetis’ products is driven by a growing population coupled with a rising middle class in emerging markets and increased relocation from rural to urban areas.

    By Samantha Nielson
  • Healthcare

    Amgen has attractive, high-growth assets

    The principal products represented 92% of Amgen’s worldwide product sales for the first half of 2014. Total product sales in 3Q14 rose 4% year-over-year, mainly driven by Kyprolis, Prolia, Neulasta, and Xgeva.

    By Samantha Nielson
  • uploads///stock picture HJHQsQohM
    Consumer

    Wellington Management: Analyzing Its Top Holdings

    Wellington Management filed its 13F on Wednesday. Based on the filing, the market value of total publicly traded securities was around $443.45 billion.

    By Rabindra Samanta
  • uploads///AdobeStock_
    Consumer

    How Are Citadel Advisors Hedging their Portfolio?

    Kenneth Cordele Griffin is the CEO of investment management firm Citadel Advisors LLC. He is the hedge fund manager and he founded Citadel in 1990. 

    By Rabindra Samanta
  • uploads///Box Pricing
    Consumer

    Must-know: How does Box make money?

    The company states that it has over 34,000 paying organizations registered.

    By Ingrid Pan
  • uploads///Ignyta Pipeline
    Company & Industry Overviews

    Ignyta’s Drug Pipeline

    Ignyta (RXDX) has completed enrollment for a Phase 1 clinical trial of RXDX-105, an orally bioavailable small molecule tyrosine kinase inhibitor.

    By Kenneth Smith
  • uploads///AdobeStock_
    Consumer

    Tech Movers: Fitbit, Roku, and Datadog Lead Gains

    The broader markets were subdued today. However, tech stocks Datadog (DDOG), Roku (ROKU) and Fitbit (FIT) gained significantly. Here’s why.

    By Adam Rogers
  • uploads///Apple Watch
    Company & Industry Overviews

    New Apple Watch Features to Focus on Digital Health

    Apple (AAPL) has partnered with Eli Lily (LLY) to research whether the iPhone and Apple Watch can identify Alzheimer’s and dementia among users.

    By Adam Rogers
  • uploads///biochemistry biology blue
    Company & Industry Overviews

    Pain and Immunology: Eli Lilly’s Key Growth Areas

    In the first quarter, Emgality, Eli Lilly and Company’s (LLY) migraine prophylaxis drug, reported revenue of $14 million, of which $12.0 million came from the US market.

    By Margaret Patrick
  • uploads///scientist _
    Company & Industry Overviews

    How Is Eli Lilly’s Revenue Trending in 2019?

    During its first-quarter earnings investor presentation, Eli Lilly and Company (LLY) guided for revenue of $22.0 billion–$22.5 billion in 2019.

    By Margaret Patrick
  • uploads///analysis background bacteria
    Company & Industry Overviews

    What Analysts Recommend for LLY and AMGN

    Eli Lilly and Company (LLY) is down 0.20%, and Amgen (AMGN) is down 3.88% in 2019 on a year-to-date basis. Investors seem disappointed with the first-quarter results of both companies.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    A Look at Cosentyx, Novartis’s Fast-Growing Immunology Drug

    In the first quarter, Novartis’s (NVS) Cosentyx reported net sales of $791 million, a YoY (year-over-year) rise of 41% on a constant currency basis.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    A Look at AstraZeneca’s and Eli Lilly’s Tax and Debt

    In fiscal 2018, AstraZeneca (AZN) and Eli Lilly (LLY) reported effective tax rates of 3% and $15.98%, respectively.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    AstraZeneca or Eli Lilly: Which Is Controlling Expenses Better?

    In its fourth-quarter earnings press release, AstraZeneca (AZN) guided for a low single-digit YoY (year-over-year) rise in core operating expenses in fiscal 2019.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    What’s Expected for AstraZeneca’s or Eli Lilly’s EPS Growth

    In its fourth-quarter earnings investor presentation, AstraZeneca (AZN) guided for core EPS of $3.50–$3.70 in fiscal 2019, expecting robust YoY (year-over-year) product sales growth and productivity improvements.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    What are AstraZeneca’s Key Growth Drivers?

    In fiscal 2018, AstraZeneca’s (AZN) revenue fell 2% YoY (year-over-year) to $22.09 billion on a CER (constant-exchange-rate) and reported basis.

    By Margaret Patrick
  • uploads///merger _
    Healthcare

    Roche Holdings to Acquire Spark Therapeutics

    On February 25, Roche Holdings (RHHBY) issued a press release announcing that it has entered a definitive agreement to acquire Spark Therapeutics (ONCE).

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    What Are Teva Pharmaceutical’s Key Growth Drivers in 2019?

    On its fourth-quarter earnings conference call, Teva Pharmaceutical (TEVA) highlighted Ajovy and Austedo as its key growth drivers for 2019.

    By Margaret Patrick
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.